Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal International Journal of Nasopharyngeal Carcinoma
Robertus Suryoseto
Radiology Departement, Center General Hospital Persahabatan, Jakarta, Indonesia.
Health Professions Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Radiotherapy with Neoadjuvant Chemotherapy on Nasopharyngeal Carcinoma (NPC) Advanced Stage Robertus Suryoseto
INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA Vol. 3 No. 01 (2021): International Journal of Nasopharyngeal Carcinoma
Publisher : TALENTA PUBLISHER

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/ijnpc.v3i01.5576

Abstract

Introduction: Nasopharyngeal carcinoma (NPC) frequently occurs in Indonesia which is endemic to several countries of Asia, specifically in southeastern China, and is associated of infection with Epstein-bar virus (EBV). In recovery, radiation therapy plays a vital role. Chemotherapy will increase the local control rate/disease control rate (DCR) in cases with an advanced local stage. Case report: A 49-year-old man felt a lump in his neck accompanied by ringing in his ears and sore throat. Physical examination showed a tumor in the right nasopharynx enlarged into the parapharynx cavity and closed Rosenmuller's fossa. The results of the biopsy were positive for non-keratinized, undifferentiated (WHO-3) type A nasopharyngeal carcinoma (NPC), moderate malignancy. The planned treatment consists of a combination of chemotherapy and radiotherapy. Chemotherapy is given 3 cycles before radiotherapy (neo adjuvant) and 3 cycles of concurrent radiotherapy (adjuvant). The total dose of radiotherapy given was 6,600 c Gy and supra clavicle 5,400 c Gy with fractionation of 33 times in the tumor and 27 times in the supra clavicle.  Conclusion: The results presented 6 months after radiotherapy were complete response to loco regional tumors with well tolerated side effects.
Co-Authors